An Alzheimer’s Drug Cut Expected Cognitive Decline Roughly in Half. It Didn’t Target Amyloid

An Alzheimer’s Drug Cut Expected Cognitive Decline Roughly in Half. It Didn’t Target Amyloid →

Researchers say the oral drug LM11A-31 slowed the decline of brain-network function in a small trial, pointing to a potential broader strategy for treating Alzheimer’s.